Low impact
Anthrax (CPB 0483, reviewed 2026-07-29)
Aetna·Effective Jul 29, 2026
Aetna's new anthrax policy (CPB 0483, effective 2026-07-29) establishes coverage criteria for anthrax vaccination in pre-exposure and post-exposure prophylaxis scenarios, laboratory testing, and treatment of active anthrax disease. The policy specifies eligible high-risk populations, FDA-approved vaccines (BioThrax, Cyfendus), antimicrobial therapies, and antitoxin drugs (raxibacumab, obiltoxaximab, AIGIV), with clear medical necessity determinations for billing purposes.